Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0YWYJJ
ADC Name
IMGN151
Synonyms
IMGN 151; IMGN-151
   Click to Show/Hide
Organization
ImmunoGen, Inc.
Drug Status
Phase 1
Indication
In total 4 Indication(s)
Endometrial cancer [ICD11:2C76]
Phase 1
Non-small cell lung cancer [ICD11:2C25]
Phase 1
Ovarian cancer [ICD11:2C73]
Phase 1
Triple negative breast cancer [ICD11:2C60-2C65]
Phase 1
Drug-to-Antibody Ratio
3.5
Antibody Name
Anti-FOLR1 mAb
  Antibody Info 
Antigen Name
Folate receptor alpha (FOLR1)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
DM21
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
100
%
KB cells
Human papillomavirus-related endocervical adenocarcinoma
Tumor Growth Inhibition value (TGI) 
100
%
IGROV-1 cells
Ovarian endometrioid adenocarcinoma
Tumor Growth Inhibition value (TGI) 
100
%
Ishikawa cells
Endometrial adenocarcinoma
Tumor Growth Inhibition value (TGI) 
100
%
OV-90 cells
Ovarian adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 100.00% High FOLR1 expression (FOLR1+++; IHC H-score=300)
Method Description
IMGN151 activity was characterized against cell lines and xenograft models with a wide range of FR expression and compared to IMGN853.
In Vivo Model KB CDX model
In Vitro Model Human papillomavirus-related endocervical adenocarcinoma KB cells CVCL_0372
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 100.00% Moderate FOLR1 expression (FOLR1++; IHC H-score=140)
Method Description
IMGN151 activity was characterized against cell lines and xenograft models with a wide range of FR expression and compared to IMGN853.
In Vivo Model IGROV-1 CDX model
In Vitro Model Ovarian endometrioid adenocarcinoma IGROV-1 cells CVCL_1304
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 100.00% Moderate FOLR1 expression (FOLR1++; IHC H-score=100)
Method Description
IMGN151 activity was characterized against cell lines and xenograft models with a wide range of FR expression and compared to IMGN853.
In Vivo Model Ishikawa CDX model
In Vitro Model Endometrial adenocarcinoma Ishikawa cells CVCL_2529
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) 100.00% Low FOLR1 expression (FOLR1+; IHC H-score=30)
Method Description
IMGN151 activity was characterized against cell lines and xenograft models with a wide range of FR expression and compared to IMGN853.
In Vivo Model OV-90 CDX model
In Vitro Model Ovarian adenocarcinoma OV-90 cells CVCL_3768
References
Ref 1 IMGN151-A next generation folate receptor alpha targeting antibody drug conjugate active against tumors with low, medium and high receptor expression. Cancer Res (2020) 80 (16_Supplement): 2890.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.